Project Funding Details

A phase I clinical trial of a mitochondrial protein synthesis inhibitor in patients with relapsed or refractory AML
Alt. Award Code
Funding Organization
Ontario Institute for Cancer Research
Budget Dates
2011-10-01 to 2014-09-30
Principal Investigator
Schimmer, Aaron D ORCiD Logo 0000-0003-4023-3899
(ORCiD iD)
University Health Network
North America
Toronto, ON, CA


View People Map
This project funding has either no collaborators or the information is not available.

Technical Abstract

Lay abstract (no permission to release technical abstract): Drugs clinically used or tested for alternate indications that have unrecognized ability to kill leukemia cells and leukemia stem cells but not normal blood cells be rapidly re-purpositoned for the treatment of leukemia given their prior safety and toxicity testing. By screening a large chemical library of old drugs, we identified Tigecycline a drug used for treatment of serious infections that has unrecognized anti-leukemia activity. Mechanistically, tigecycline acted as an anti-leukemic agent by inhibiting mitochondrial protein synthesis. Here, we propose to rapidly advance this drug into clinical trial for patients with relapsed/refractory leukemia and initiate a phase I clinical trial of tigecycline in patients with this disease. In the context of this trial, we will measure levels of tigecycline in the blood and leukemia cells. We will also conduct “proof-of-mechanism” studies to determine whether tigecycline is inhibiting mitochondrial protein synthesis in our patients. Thus, this drug will be a first-in-class therapy for patients with cancer.

Public Abstract

See Tech Abstract

Cancer Types

  • Leukemia / Leukaemia

Common Scientific Outline (CSO) Research Areas

  • 5.4 Treatment Systemic Therapies - Clinical Applications